SUMMARY Three monoclonal antibodies MT1, L60 , and DF-Tl, were reported independently as recognising human T cells in routinely processed, paraffin wax embedded tissue. The present study was performed to compare these three reagents in terms of their immunocytochemical reactions and target molecule(s). On Western blotting of white cell extracts the three antibodies reacted with antigens of the same molecular weight (range 110-160 kilodaltons). Furthermore, their immunocytochemical reactivity with normal human cells, as analysed by two-colour flow cytometry, was essentially identical (labelling ofmonocytes, most T lymphocytes, and weak reactions with some B cells), and the antibodies gave closely similar reactions on 54 white cell derived neoplasms. To identify the target antigen for these three reagents, antibodies from the Third International Workshop on Leucocyte Antigens were reviewed and it was shown that the Western blotting and immunocytochemical reactions of MTl, L60 (Leu-22), and DF-T1 were identical with those of the reagents which defined the CD43 antigen (also known as leucosialin or sialophorin). Furthermore, all these antibodies reacted with cells transfected with a cDNA clone encoding CD43. It is concluded that antibodies MTl, L60 (Leu-22), and DF-T1 all recognise the heavily glycosylated myeloid/lymphoid associated CD43 antigen.
. Mononuclear cells were fractionated by centrifugation through Percol: 1 sg 1-06 (Pharmacia). Lymphocytes and monocytes were more than 95% pure. Granulocytes were obtained from the resuspended cell pellets by sedimentation of erythrocytes with 4% Dextran 150 (BDH) in phosphate buffered saline (PBS). Cells were washed three times in PBS and 2 x 10' cells solubilised in 1 ml of 0 5% Nonidet P40 (BDH) containing 1 mM phenylmethyl-sulphonylfluoride (Sigma) and 20 mM ethylene glyco-bis (amino ethyl ether) N,N,N',N'-tetra acetic acid (Sigma). MTl, DF-Tl, and L60 (Leu-22) was more easily appreciated.
Thymus sections showed strong labelling of most cells in both the cortex and the medulla, similar to anti-CD3.
Bone marrow smears showed strong labelling of myeloid cells, megakaryocytes, and erythroid precursors with DF-Tl, MTI, and L60 (Leu-22) (fig 5) . Platelets and red cells were unstained, as were occasional cells of lymphoid morphology.
When compared with normal tissues (using paraffin wax sections of tonsil and cryostat sections of tonsil, thymus, and brain) the three anti-CD43 antibodies seemed to be identical with DF-Tl.
Lymphoid neoplasms Antibodies MT1, DF-TI, and L60 (Leu-22) showed similar patterns of reactivity on paraffin wax sections from 37 haematolymphoid malignancies. In general, T cell lymphomas showed identical patterns of staining with the three antibodies (table 3, fig 6) .
Reactivity of B cell tumours was most commonly Transfectants COS-7-cells transfected with the CD43 gene reacted strongly with DF-T1, MT1, and L60 (Leu-22) and also with antibodies known to recognise CD43 (84-3C, G19-1, and G10-2) both by flow cytometry (data not shown) and by APAAP (fig 1 1) Equivalent results were obtained with MT1, DF-T1, L60 (Leu-22) and the three anti-CD43 antibodies when they were compared on normal tissue sections. The patterns of reactivity obtained in tissue sections with myeloid cells, T cells, and some B cell tumours is consistent with the limited data obtained by flow cytometry in the Third Workshop.' Double staining experiments by flow cytometry showed that CD43 was also found on some non-malignant B cells, usually at lower levels than T cells. The demonstration of CD43 antigen on B cells at levels below the threshold of standard immunohistological staining of tissue sections may be relevant to the finding that some cases of B cell neoplasia are positive for the antigen. Similarly, the existence of a few normal T cells which lack the CD43 antigen may account for T cell lymphomas with this phenotype.
The view that the six antibodies all detect the same molecule was independently corroborated by showing that the COS-7 monkey kidney cell line, which had been induced to express the CD43 antigen by transfection of the CD43 gene, was recognised by all six antibodies.
Antibodies MTI, DF-Tl, and L60 (Leu-22) were also compared for their reactivity with previously phenotyped tumours. The antibodies were broadly equivalent but some discrepancies in the staining patterns were found. The differences were most evident when staining B cell neoplasms on which the antigen, when present, is often only weakly expressed. Reports of the rate at which MTI reacts with B cell tumours in paraffin wax sections show considerable differences, ranging from 0-49% (table 4) , and variability in MTI staining caused by differences in fixation time has been noted previously.32 These results suggest that technical variables, such as fixation, enzymatic digestion, and staining, or differences in antibody avidity may influence the threshold for positive staining in paraffin wax sections, particularly when the antigen is present at low concentrations. It is of relevance that no differences between the reactions of the antibodies MTI, DF-Tl, and L60 (Leu-22) were seen on CLL blood smears (in which there was less possibility of fixation and processing artefacts). Thus even when it is clear from biochemical studies that antibodies recognise the same molecule, differences in the staining reactions in sections from the same tumour do occur.
The observation that the antigen recognised by the six antibodies is found on some B cell tumours is reminiscent of CD5 expression on B cell CLL and some B cell lymphomas. The mechanism ofexpression on B CLL cells, however, is likely to be. different for CD5 and CD43 because cases of CLL were encountered in which either one ofthese antigens was found in the absence of the other.
In conclusion, the antibody MTl, widely used for detecting T cells in paraffin wax sections, is not a unique reagent but belongs to the CD43 cluster first described in 1986. DF-Tl and L60 (Leu-22) also recognise the same molecule, and the three antibodies give broadly equivalent immunostaining on routinely processed tissue sections. It is clear that CD43 antigen is expressed on a proportion of B cell neoplasms, so that staining for this molecule, when phenotyping lymphoid proliferations, should always be accompanied by staining for other independent T cell markers such as anti-CD333 and UCHL1L. 3 The findings of our paper should help to prevent pathologists inadvertently staining with two anti-CD43 antibodies in the belief that they are detecting different T associated antigens.
Anti-CD43 antibodies may also be of value in showing that a T cell proliferation is neoplastic, because ofthe non-reactivity ofthe T cells, as has been shown with antibody L60 (Leu-22).5 The same study also showed that the expression of CD43 on B cell proliferations correlated with malignancy.
Finally, the reactivity with myeloid cells may be of practical value in providing additional evidence that cells are of this lineage. An example of this application is to be found in the report by Facchetti et al,35 that "'plasmacytoid T cells" react with the anti-CD43 antibody MT 1, but not with other anti-T cell reagents, providing evidence for a myeloid rather than a T cell origin.
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